Skip to main content
2025 DC/CSEM Professional Conference Main banner
On-Demand

Rare Disease Rounds

RDRS1 - Sharp Needles in the Crowd: Fresh approaches to common challenges in pituitary endocrinopathies

Thursday, November 27, 2025
13:00 - 14:15 Toronto
Location: Room 205

    Speaker(s)

  • Shereen Ezzat, MD, FRCP(C), FACP (he/him/his)

    Professor of Medicine & Oncology
    Princess Margaret Cancer Centre/University Health Network
    University of Toronto/Princess Margaret Cancer Centre
    Toronto, Ontario, Canada

    Disclosure(s): Ipsen: Advisory Board (Ongoing); Merck, Pfizer, Ipsen, Eisai, Novartis: Advisory Board (Ongoing)

  • Luciana Martel-Duguech, MD, PhD

    Assistant Professor, Clinician-Scientist, Staff Endocrinologist,
    Department of Medicine Division of Endocrinology and Metabolism, University of Ottawa Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital
    Ottawa, Ontario, Canada

    Disclosure(s): Recordati Rare Disease: Board Member (Terminated, November 8, 2025), Grant/Research Support (Terminated, November 8, 2025)

  • JM

    JESSICA M. MACKENZIE-FEDER, MDCM (she/her/hers)

    Endocrinologist
    University of British Columbia
    University of British Columbia
    Vancouver, British Columbia, Canada

    Disclosure(s): Pfizer: Advisory Board (Terminated, January 23, 2025), Advisory Board (Terminated, January 23, 2025); Recordati Rare Disease: Speaker/Honoraria (Terminated, September 28, 2024), Speaker/Honoraria (Terminated, September 28, 2024)

    • Moderator(s)

  • Matthieu St-Jean, n/a (he/him/his)

    Endocrinologist
    Université de Sherbrooke
    Université de Sherbrooke
    Sherbrooke, Quebec, Canada

    Disclosure(s): GlaxoSmithKline: Advisory Board (Terminated, June 13, 2024), Speaker/Honoraria (Terminated, June 13, 2024); Medunk: Advisory Board (Terminated, March 19, 2025), Speaker/Honoraria (Terminated, March 19, 2025); Recordati Rare Diseases Canada: Consultant (Terminated, January 20, 2025), Speaker/Honoraria (Terminated, January 20, 2025)

Disclosure(s):
Shereen Ezzat, MD, FRCP(C), FACP: Ipsen: Advisory Board (Ongoing); Merck, Pfizer, Ipsen, Eisai, Novartis: Advisory Board (Ongoing)
Luciana Martel-Duguech: Recordati Rare Disease: Board Member (Terminated, November 8, 2025), Grant/Research Support (Terminated, November 8, 2025)
JESSICA M. MACKENZIE-FEDER, MDCM: Pfizer: Advisory Board (Terminated, January 23, 2025), Advisory Board (Terminated, January 23, 2025); Recordati Rare Disease: Speaker/Honoraria (Terminated, September 28, 2024), Speaker/Honoraria (Terminated, September 28, 2024)
Matthieu St-Jean, n/a: GlaxoSmithKline: Advisory Board (Terminated, June 13, 2024), Speaker/Honoraria (Terminated, June 13, 2024); Medunk: Advisory Board (Terminated, March 19, 2025), Speaker/Honoraria (Terminated, March 19, 2025); Recordati Rare Diseases Canada: Consultant (Terminated, January 20, 2025), Speaker/Honoraria (Terminated, January 20, 2025)
This program is co-developed with Novo Nordisk, Pfizer, and Recordati and planned independently by CSEM to achieve scientific integrity, validity, and balance. An unrestricted educational grant was received from Novo Nordisk, Pfizer, and Recordati.

Learning Objectives:

  • Recognize and assess Adult Growth Hormone Deficiency (GHD) Syndrome
  • Review nuances in GHD diagnosis and treatment
  • Apply a case-based approach to recognize early clinical signs of acromegaly in metabolic patients and understand the diagnostic pitfalls that may delay appropriate intervention
  • Distinguish Cushing’s disease from uncomplicated metabolic syndrome by recognizing key discriminatory clinical features and by selecting and interpreting contemporary screening tests accurately and efficiently